scholarly journals A glycosyltransferase gene signature to detect pancreatic ductal adenocarcinoma patients with poor prognosis

EBioMedicine ◽  
2021 ◽  
Vol 71 ◽  
pp. 103541
Author(s):  
Yousra Mohamed Abd-El-Halim ◽  
Abdessamad El Kaoutari ◽  
Françoise Silvy ◽  
Marion Rubis ◽  
Martin Bigonnet ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Gene Signature ◽  
Ductal Adenocarcinoma ◽  
Glycosyltransferase Gene ◽  
Patients With Poor Prognosis

scholarly journals Identification and Validation of Circulating Micrornas as Prognostic Biomarkers in Pancreatic Ductal Adenocarcinoma Patients Undergoing Surgical Resection

2020 ◽  
Vol 9 (8) ◽  
pp. 2440
Author(s):  
Natalia Gablo ◽  
Karolina Trachtova ◽  
Vladimir Prochazka ◽  
Jan Hlavsa ◽  
Tomas Grolich ◽  
...  
Keyword(s):  
Blood Plasma ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Surgical Resection ◽  
Poor Prognosis ◽  
Ductal Adenocarcinoma ◽  
Small Rna Sequencing ◽  
High Morbidity ◽  
Plasma Samples ◽  
Circulating Micrornas ◽  
Patients With Poor Prognosis

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal and aggressive cancers with a less than 6% five-year survival rate. Circulating microRNAs (miRNAs) are emerging as a useful tool for non-invasive diagnosis and prognosis estimation in the various cancer types, including PDAC. Our study aimed to evaluate whether miRNAs in the pre-operative blood plasma specimen have the potential to predict the prognosis of PDAC patients. In total, 112 PDAC patients planned for surgical resection were enrolled in our prospective study. To identify prognostic miRNAs, we used small RNA sequencing in 24 plasma samples of PDAC patients with poor prognosis (overall survival (OS) < 16 months) and 24 plasma samples of PDAC patients with a good prognosis (OS > 20 months). qPCR validation of selected miRNA candidates was performed in the independent cohort of PDAC patients (n = 64). In the discovery phase of the study, we identified 44 miRNAs with significantly different levels in the plasma samples of the group of good and poor prognosis patients. Among these miRNAs, 23 showed lower levels, and 21 showed higher levels in plasma specimens from PDAC patients with poor prognosis. Eleven miRNAs were selected for the validation, but only miR-99a-5p and miR-365a-3p were confirmed to have significantly lower levels and miR-200c-3p higher levels in plasma samples of poor prognosis cases. Using the combination of these 3-miRNA levels, we were able to identify the patients with poor prognosis with sensitivity 85% and specificity 80% (Area Under the Curve = 0.890). Overall, 3-miRNA prognostic score associated with OS was identified in the pre-operative blood plasma samples of PDAC patients undergoing surgical resection. Following further independent validations, the detection of these miRNA may enable identification of PDAC patients who have no survival benefit from the surgical treatment, which is associated with the high morbidity rates.

scholarly journals Aberrant methylation ofReprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma

Cancer ◽  
2006 ◽  
Vol 107 (2) ◽  
pp. 251-257 ◽  
Author(s):  
Norihiro Sato ◽  
Noriyoshi Fukushima ◽  
Hiroyuki Matsubayashi ◽  
Christine A. Iacobuzio-Donahue ◽  
Charles J. Yeo ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Genetic Instability ◽  
Poor Prognosis ◽  
Ductal Adenocarcinoma ◽  
Aberrant Methylation

High expression of ErbB3 binding protein 1 (EBP1) predicts poor prognosis of pancreatic ductal adenocarcinoma (PDAC)

Tumor Biology ◽  
2015 ◽  
Vol 36 (12) ◽  
pp. 9189-9199 ◽  
Author(s):  
Chen Gong ◽  
Yixin Zhang ◽  
Yinji Chen ◽  
Haifeng Zhang ◽  
Xiaorong Liu ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Binding Protein ◽  
High Expression ◽  
Ductal Adenocarcinoma

SLC39A1 Contributes to Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma by Activating AMPK Signaling

2021 ◽  
Author(s):  
Hao Yu ◽  
Xiaoping Mei ◽  
Xueming Zhang ◽  
Neng Qian ◽  
Qingjiang Yu ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Protein Expression ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Western Blotting ◽  
Poor Prognosis ◽  
Ductal Adenocarcinoma ◽  
Tumor Type ◽  
Ampk Signaling ◽  
Gemcitabine Resistance ◽  
Mrna And Protein Expression

Abstract Objective: Pancreatic ductal adenocarcinoma (PDAC) serves as a prevailing tumor type with high mortality and poor prognosis. The study aims to explore the mechanism of gemcitabine resistance in PDAC patients. Methods: Immunohistochemistry(IHC)was used to analyze the expression of SLC39A1 in PDAC samples. PDAC cells were culture and transfected with siSLC39A1 and siNC, respectively. Cell proliferation analysis was performed using CCK-8 assay. And qPCR and Western blotting was used to analysis the expression level of SLC39A1 and related signal molecular in cells. Results: IHC results demonstrated that the SLC39A1 expression was significantly up-regulated in the gemcitabine-resistant PDAC samples compared with gemcitabine-sensitive PDAC samples. The treatment of gemcitabine dose-dependently inhibited the viability of the PDAC cells. Meanwhile, the mRNA and protein expression of SLC39A1 were elevated in the gemcitabine-resistant PDAC. The treatment of gemcitabine remarkably decreased viability of PDACs, in which SLC39A1 depletion could reverse this effect. SLC39A1 knockdown could reverse the gemcitabine-induced phosphorylation of AMPK enhanced and gemcitabine-inhibited S6K expression. Conclusion: SLC39A1 contributed to gemcitabine resistance of PDAC by activating AMPK signaling.

Adipophilin expression is an indicator of poor prognosis in patients with pancreatic ductal adenocarcinoma: An immunohistochemical analysis

Pancreatology ◽  
2019 ◽  
Vol 19 (3) ◽  
pp. 443-448 ◽  
Author(s):  
Yuki Hashimoto ◽  
Mitsuaki Ishida ◽  
Hironori Ryota ◽  
Tomohisa Yamamoto ◽  
Hisashi Kosaka ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Immunohistochemical Analysis ◽  
Ductal Adenocarcinoma

scholarly journals Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma

2020 ◽  
Vol 123 (1) ◽  
pp. 72-80
Author(s):  
Fabien Robin ◽  
Gaëlle Angenard ◽  
Luis Cano ◽  
Laetitia Courtin-Tanguy ◽  
Elodie Gaignard ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Molecular Profiling ◽  
Ductal Adenocarcinoma

scholarly journals High Expression of Cancer-Derived Glycosylated Immunoglobulin G Predicts Poor Prognosis in Pancreatic Ductal Adenocarcinoma

2020 ◽  
Vol 11 (8) ◽  
pp. 2213-2221
Author(s):  
Ming Cui ◽  
Lei You ◽  
Bang Zheng ◽  
Xinmei Huang ◽  
Qiaofei Liu ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Immunoglobulin G ◽  
Poor Prognosis ◽  
High Expression ◽  
Ductal Adenocarcinoma

scholarly journals Aberrant MicroRNAs in Pancreatic Cancer: Researches and Clinical Implications

2014 ◽  
Vol 2014 ◽  
pp. 1-11 ◽  
Author(s):  
Tao Sun ◽  
Xiangyu Kong ◽  
Yiqi Du ◽  
Zhaoshen Li
Keyword(s):  
Pancreatic Cancer ◽  
Pancreatic Ductal Adenocarcinoma ◽  
Poor Prognosis ◽  
Vital Role ◽  
High Rate ◽  
Ductal Adenocarcinoma ◽  
Clinical Implications ◽  
Circulating Mirnas ◽  
Current Review ◽  
Wide Range

Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with a high rate of mortality and poor prognosis. Numerous studies have proved that microRNA (miRNA) may play a vital role in a wide range of malignancies, including PDAC, and dysregulated miRNAs, including circulating miRNAs, are associated with PDAC proliferation, invasion, chemosensitivity, and radiosensitivity, as well as prognosis. Greater understanding of the roles of miRNAs in PDAC could provide insights into this disease and identify potential diagnostic markers and therapeutic targets. The current review focuses on recent advances with respect to the roles of miRNAs in PDAC and their practical value.

Sign in / Sign up

Export Citation Format

Share Document